How can you resolve the complexities of precision medicine to give cancer patients the best chance at the best outcomes?
Trapelo knows.
Trapelo is the first, interoperable, decision-support platform used by oncologists, labs, and payers that informs testing and treatment, streamlines workflow and facilitates real-time alignment in precision medicine. Trapelo obviates the need for traditional prior authorization, enabling value-based care while quickly giving patients the most appropriate, evidence-supported options when time matters most.
Learn more about what Trapelo knows:
“Implementing precision medicine is no longer just a possibility, it is practically imperative. Cancer patients can’t wait.”
– Michael A. Caligiuri, M.D., President, City of Hope National Medical Center
Listen to the award-winning podcast featuring today's precision medicine innovators.
.jpg)
Featured Guests:
-
Mr. Chet Burrell, formerly CareFirst Blue Cross Blue Shield
-
Dr. Jack West, City of Hope
-
Clynt Taylor, Trapelo Health
-
Luba Greenwood, Google Life Sciences
Listen to the award-winning podcast featuring today's precision medicine innovators.
_SM.png)
Guests include patient advocates, oncologists, educators, entrepreneurs, genomic scientists, pathologists, health plan executives and more including:
-
Lisa Goldman and Tori Tomalia, lung cancer patients and ROS1der founders
-
Dr. John Quackenbush, Harvard School of Public Health
-
Dr. Arturo Loaiza-Bonilla, Cancer Treatment Centers of America
-
Erika Stringer-Reasor, University of Alabama Birmingham
-
Barbara Fortini, PhD, Keck Graduate Institute
-
Dr. Clayton Yates, Tuskegee University
-
Dr. Lee Newcomer, ret. UnitedHealthcare
-
Dr. Windy Dean-Columb, Our Lady of Lourdes Regional Medical Center
-
Dr. Bruce Johnson, Dana Farber Cancer Institute
-
Chet Burrell, formerly CareFirst Blue Cross Blue Shield
-
Dr. Jack West, City of Hope
-
Selin Kurnaz, Massive Bio
-
Clynt Taylor, Trapelo Health
-
Luba Greenwood, Google Life Sciences